Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. [GOC:mah]
Phospholipid biosynthesis, a vital process for cell membrane construction and function, is meticulously regulated to ensure proper membrane integrity and signaling. This intricate regulatory network involves a complex interplay of transcriptional, translational, and post-translational mechanisms, fine-tuning the production of phospholipids to meet the dynamic needs of the cell.
**Transcriptional Regulation:**
Gene expression of enzymes involved in phospholipid synthesis is modulated by transcription factors, which respond to cellular signals and environmental cues. For example, the sterol regulatory element-binding protein (SREBP) family plays a crucial role in regulating the synthesis of phospholipids and cholesterol. When cellular levels of cholesterol and phospholipids decline, SREBPs are activated, promoting the transcription of genes encoding enzymes involved in their biosynthesis.
**Translational Regulation:**
Translation of mRNAs encoding phospholipid synthesis enzymes is also regulated. MicroRNAs (miRNAs), small non-coding RNAs, can bind to specific target mRNAs and inhibit their translation. This mechanism fine-tunes the production of phospholipid synthesis enzymes in response to cellular signals and environmental changes.
**Post-translational Regulation:**
Post-translational modifications, such as phosphorylation, acetylation, and ubiquitination, can modulate the activity of phospholipid synthesis enzymes. These modifications can affect enzyme stability, localization, and catalytic activity, ultimately influencing phospholipid production.
**Feedback Mechanisms:**
Phospholipid biosynthesis is subject to feedback regulation. The end products of phospholipid synthesis, such as phosphatidylcholine and phosphatidylethanolamine, can act as feedback inhibitors, reducing the activity of key enzymes involved in their synthesis. This feedback loop ensures that phospholipid levels are maintained within a specific range.
**Cellular Signaling Pathways:**
Numerous signaling pathways, including the insulin, mTOR, and Wnt pathways, influence phospholipid biosynthesis. These pathways regulate the activity of key transcription factors and enzymes involved in phospholipid production, ensuring that the process is integrated with other cellular processes.
**Dynamic Regulation:**
The regulation of phospholipid biosynthesis is highly dynamic, adapting to changes in cell growth, differentiation, and environmental conditions. This intricate regulatory network ensures that the cell can maintain membrane integrity, support signaling events, and respond to various stimuli.'
"
Protein | Definition | Taxonomy |
---|---|---|
Isocitrate dehydrogenase [NADP] cytoplasmic | An isocitrate dehydrogenase [NADP] cytoplasmic that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ciclopirox | cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone | antibacterial agent; antiseborrheic | |
zuclomiphene | Zuclomiphene: The cis or (Z)-isomer of clomiphene. | stilbenoid | |
mangostin | alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. mangostin: xanthone from rind of Garcinia mangostana Linn. fruit | aromatic ether; phenols; xanthones | antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite |
licochalcone a | licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer | chalcones | |
gamma-mangostin | gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity. | phenols; xanthones | antineoplastic agent; plant metabolite; protein kinase inhibitor |
beta-Mangostin | xanthones | ||
nsc-287088 | |||
SYC-435 | SYC-435 : A cyclic hydroxamic acid that is 1-hydroxypyridin-2(1H)-one in which the hydrogens at positions 4 and 6 are substituted by methyl and benzyl groups, respectively. It is a potent inhibitor of mutant isocitrate dehydrogenase 1 (Ki values of 190 nM against R132H mutant and 120 nM against R132C mutant). | benzenes; cyclic hydroxamic acid; pyridone | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |
agi-5198 | AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source | ||
agi-6780 | AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source | ||
ivosidenib | ivosidenib : A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. ivosidenib: an inhibitor of isocitrate dehydrogenase 1 (IDH1) for treatment of acute myeloid leukemia (AML) | cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |
enasidenib | 1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |